Featured Education

Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches

Click here to learn more

Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients

Click here to learn more

Patient Perspectives for PCPs - Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders

Click here to learn more

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Click here to learn more

Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies

Click here to learn more

Build Your Own Case Study | Obesity: Treating the Whole Patient

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • November 29, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing
Enroll Today
View Course
  • On-Demand
Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches
  • Credit: 1.0hr(s)
  • CME, CPE, ECMEC, MOC, NCPD
  • September 28, 2023 — 
  • September 27, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Lymphoma
  • Location: Internet Activity Enduring
New and emerging advancements in the treatment of follicular lymphoma (FL) are on the horizon. Are you and your clinical teams up for the challenge of testing your skill in applying the latest clinical evidence to these groundbreaking therapies? This independent satellite symposium is an engaging learning experience, where you’ll have the chance to compete against your colleagues in complex clinical cases of follicular lymphoma.
Enroll Today
View Course
  • On-Demand
Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 8, 2023 — 
  • February 8, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Multiple Myeloma
  • Location: Internet Activity Enduring
Treatment strategies for relapsed/refractory multiple myeloma (RRMM) are inevitably complex as oncology teams must consider patient-, treatment-, and disease-related factors in their decision-making. Tune into the last episode of the Med Table Talk® Series on Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy
Enroll Today
View Course
  • On-Demand
Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • January 26, 2023 — 
  • February 8, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Multiple Myeloma
  • Location: Internet Activity Enduring
B-cell maturation antigen (BCMA) plays a promising role as a therapeutic target. In fact, several BCMA-directed therapy modalities, including bispecific antibodies, chimeric-antigen receptor T-cell (CART), and antibody-drug conjugates, are available or in development for patients with relapsed/refractory multiple myeloma (RRMM). Even with the advances in the treatment regime, it is important for oncology teams to understand the implications of the clinical data. Tune into the 1st episode of the Med Table Talk® Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy, where our leading experts will discuss: The rationale, mechanism of action, and efficacy and safety of currently available BCMA-directed therapies Prevention and management strategies for adverse events associated with BCMA agents The unmet need for representation in clinical trials
Enroll Today
View Course
  • On-Demand
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 17, 2023 — 
  • February 16, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: NSCLC, Oncology
  • Location: Internet Activity Enduring
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Enroll Today
View Course
  • On-Demand
GVHD 5 - ECHO Program: Atypical Manifestations of Chronic GVHD
  • Credit: 1.0hr(s)
  • December 8, 2022 — 
  • December 8, 2023
  • Therapeutic Areas: Dermatology, Family Medicine / Primary Care, Internal Medicine, Rheumatology
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care. The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients. Questions and comments from the learners will be encouraged to facilitate discussion.
Enroll Today
View Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top